



## SINGAPORE ASSOCIATION OF PHARMACEUTICAL INDUSTRIES

151 Chin Swee Road, #02-13A/14, Manhattan House, Singapore 169876.

T: +65-6738 0966 F: +65-6738 0977 E: [admin@sapi.org.sg](mailto:admin@sapi.org.sg) W: [www.sapi.org.sg](http://www.sapi.org.sg) UEN: S66SS0025J

### **Singapore Association of Pharmaceutical Industries Announces Newly-Elected President and Vice Presidents**

August 2, 2024, SINGAPORE— The Singapore Association of Pharmaceutical Industries (SAPI) announced that its board of directors has re-elected Ms. Poh Hwee Tee, Country President of Novartis, as President of the association, effective immediately. Additionally, Ms. Yeoh Ying Ying, General Manager of Roche, will continue as Vice-President, alongside the newly elected Vice-President, Dr. Abdullahi Sheriff, Managing Director of MSD.

As President, Ms. Poh will continue to represent SAPI in all matters, focusing on fostering greater collaborations with policymakers, healthcare providers, patient groups, and other stakeholders to improve access to innovative medicines and vaccines. Established in 1966, SAPI currently comprises 43 members, including 38 global biopharmaceutical companies in Singapore, employing close to 10,000 people in the country. Manufacturing output of pharmaceutical and biological products in 2023 amounted to close to \$15 billion, accounting for close to 4 percent of Singapore's manufacturing activity.

“Hwee Tee boosted SAPI's industry engagement and advanced our collective goals as a valued and trusted industry partner within Singapore's healthcare ecosystem. I thank her for her strong leadership, commitment and significant contributions to SAPI,” said SAPI's Executive Director Christina Teo. “I am confident that Hwee Tee will continue to strengthen SAPI's strategic advocacy efforts with key stakeholders and enhance access to innovative medicines and vaccines in Singapore as we work towards advancing Singapore's position as a global biopharmaceutical hub and supporting the country in achieving its healthcare objectives.”

Ms. Poh brings extensive experience and a proven track record of leadership to the role. As Country President for Singapore & Asian Emerging Markets at Novartis Singapore, Ms. Poh has accumulated over 25 years of expertise in the biopharmaceutical sector, successfully leading various functions including marketing, sales, and operations. Her previous tenure as Vice-President of SAPI in 2021 and her dedicated service as Chair of SAPI's Research & Development Committee from July 2020 to 2022 highlight her deep commitment to advancing the association's mission.

Dr. Sheriff, appointed to SAPI's Board of Directors in 2023, brings extensive experience from his role as Managing Director for MSD in Singapore, Malaysia, and Brunei. He has a strong track record of building high-performing teams, advancing health system solutions, and forging partnerships. His experience spans diverse therapeutic areas, including oncology and vaccines, and geographies such as the UK, Europe, Asia, and the US. His previous consulting experience with the UK NHS on health system reforms makes him ideally suited to contribute positively in his roles as Vice-President and Chair of SAPI's Public Policy Committee.

Ms Yeoh has held the position of Vice President of SAPI since 2022 and has been reappointed for the current term. She also continues her leadership as Chair of SAPI's Research & Development committee. As General Manager of Roche, she brings more than 18 years of experience in the pharmaceutical industry to SAPI, including managing diverse portfolios in oncology, ophthalmology, haematology and neuroscience across Asia, Europe and the US. Her deep and diverse connections within Singapore's healthcare ecosystem make her an invaluable asset to the Board.

“SAPI remains committed to building strong, sustainable partnerships with our stakeholders amid the rapidly evolving healthcare landscape in Singapore. I am honored by the trust my colleagues have placed in me and look forward to working closely with them to enhance dialogue and strengthen relationships across the healthcare ecosystem. Together, we aim to broaden and accelerate access to innovative medicines and vaccines for patients in Singapore,” said Ms Poh.

---

For media queries, please contact:  
Ms. Xu Meng  
Public Affairs and Communications Manager  
Singapore Association of Pharmaceutical Industries  
Email: [xu.meng@sapi.org.sg](mailto:xu.meng@sapi.org.sg)  
Website: <https://www.sapi.org.sg/>

### ***About SAPI***

Founded in 1966, the Singapore Association of Pharmaceutical Industries (SAPI) is a non-profit industry trade association representing 43 members, including 38 global R&D-based biopharmaceutical companies in Singapore. SAPI is dedicated to advancing the accessibility of innovative medicines for patients in Singapore. This mission is achieved through fostering sustainable and valued partnerships with healthcare professionals, providers, government bodies, and patient group stakeholders, underpinned by the highest standards of ethical behaviour.

For more information about SAPI and its initiatives, please visit [www.sapi.org.sg](http://www.sapi.org.sg) and follow SAPI on [LinkedIn](#).